Journal of Histochemistry and Cytochemistry, Vol. 48, 1609-1616, December 2000, Copyright © 2000, The Histochemical Society, Inc.


ARTICLE

A New Monoclonal Anti-CD3{varepsilon} Antibody Reactive on Paraffin Sections

Laeticia Alibauda, Régine Lloberaa, Talal Al Saatia, Michel Marcha, Georges Delsola, and Bent Rubina
a Unité de Physiopathologie Cellulaire et Moléculaire, CNRS-UPR 2163, Institut Claude de Preval, IFR 30, Chu de Purpan, Toulouse, France

Correspondence to: Georges Delsol, Unité de Physiopathologie Cellulaire et Moléculaire, CNRS-UPR 2163, Institut Claude de Preval, IFR 30, Chu de Purpan, 31059 Toulouse, Cedex 03, France. E-mail: rubin@immgen.cnrs.fr


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

We generated a new monoclonal antibody (MAb), F7.2.38, by immunizing mice with CD3{varepsilon}{gamma}{delta}/CD3{omega} complexes purified from human T-cells by OKT3 MAb–Sepharose affinity chromatography. Immunoprecipitation experiments and Western blotting analysis showed that MAb F7.2.38 recognized the CD3{varepsilon} chain in CD3{varepsilon} cDNA-transfected FOX B-cells and in various T-cell lines. Using flow cytometry on permeabilized or intact cells, the epitope was found to be located in the cytoplasmic tail of the CD3{varepsilon} chain. Immunohistochemical staining on paraffin-embedded sections showed that the reactivity of MAb F7.2.38 was comparable to that of the commercially available anti-CD3{varepsilon} polyclonal antibody. Of the 52 well-characterized T-cell lymphomas, 41 were positive for F7.2.38 (79%), whereas all 37 B-cell lymphomas and 69 non-lymphoid tumors were unreactive. This new anti-CD3{varepsilon} antibody would be particularly useful for phenotyping T-cell lymphomas on routinely processed paraffin-embedded tissue sections. (J Histochem Cytochem 48:1609–1616, 2000)

Key Words: monoclonal antibody, CD3{varepsilon} chain, T-cell lymphomas, T-cell receptor assembly, immunohistochemistry, paraffin sections


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

THE T-CELL RECEPTOR is composed of two clonotypic chains, TCR{alpha} and TCRß, non-covalently associated with the invariant chains called CD3{gamma}, CD3{delta}, CD3{varepsilon}, and {zeta} (Clevers et al. 1988 ; Manolios et al. 1991 ; Rubin et al. 1994 ). Monoclonal antibodies (MAbs) against the individual components of the TCR/CD3 complex have been useful tools in analyzing T-cell receptor complex structure and assembly. MAbs against TCR{alpha} or TCRß variable and constant regions, or external and cytoplasmic domains of CD3{varepsilon} chain, have been produced by immunizing mice, rats, or hamsters with human T-cell clones or lymphomas. The anti-CD3{varepsilon} MAbs are directed against two different types of epitopes: (a) unique "conformational epitopes" created in CD3{gamma}{varepsilon} or CD3{delta}{varepsilon} heterodimers, and (b) epitopes on isolated CD3{varepsilon} chains (Pessano et al. 1985 ; Alarcon et al. 1991 ; Salmeron et al. 1991 ; San Jose et al. 1998 ). However, MAbs against the extracellular parts of CD3{gamma} or CD3{delta} chains have never been obtained. This could be due either to amino acid sequence similarity between CD3 molecules of donor and recipient species or to lack of accessibility of the CD3 molecules to the immune system. However, there appear to be ample differences in amino acid sequences between CD3{gamma} and CD3{delta} molecules from human and mouse (see Gold et al. 1987 ; Clevers et al. 1988 ; Salmeron et al. 1991 ). Therefore, it may be that potential immunogenic epitopes on these molecules are not presented to antigen-recognizing T- and B-cells in the immunized animals, although why this should be is not clear.

These considerations have led us to develop methods for the production of MAbs against all components of known human TCR/CD3 complexes (pre-TCR, TCR{gamma}{delta}, or TCR{alpha}ß). Such MAbs will be very useful for studies on TCR/CD3 structure and in the characterization of TCR complexes on T-lymphocytes in various diseases such as immunodeficiency, allergy, autoimmunity, and cancer. Our goal has been to produce MAbs useful in many different analytical systems, i.e., cytofluometry on living or permeabilized cells, immunohistochemistry on tissue sections prepared by different methods, immunoprecipitation in different detergents, and Western blotting analyses. Because immunization with living T-cells has been unsuccessful, we attempted to isolate CD3 complexes from NP40-T cell lysates on anti-CD3{varepsilon} MAb affinity columns. Mice were injected with the eluted material, which contained mainly CD3{gamma}, {delta}, and {varepsilon} molecules, plus an intracellular chaperone, CD3{omega}, implicated in CD3 complex assembly (Pettey et al. 1987 ; Neisig et al. 1993 ).

Here we present the characterization of one of the MAbs obtained using this strategy. The MAb, F7.2.38, directed against a cytoplasmic epitope in the CD3{varepsilon} chain, recognizes an epitope present in both frozen and formalin-fixed material. The reactivity of this antibody was compared with that obtained using the commercially available rabbit anti-CD3{varepsilon} antibody (Dako; Trappes, France).


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Production of MAb F7.2.38
CD3 complexes were obtained by affinity chromatography of 2% NP-40 detergent (Fluka Chemie; Buchs, Switzerland)-solubilized proteins from Jurkat T-cells (250–500 x 106 cells/immunization/mouse) on a 5-ml Sepharose bead column (Amersham Pharmacia Biotech; Orsay, France) with covalently coupled MAb OKT3. Elution was performed with 1 M NH4SCN or 0.2 M glycine buffer, pH 2.8. F1 hybrid female mice (C57B6 x Balb/c) were immunized three times, once SC and twice IP, with eluted material in 250 µl of DPBS (NaCl 0.14 M, Na2HPO4 8 mM, KH2PO4 1.5 mM, KCl 2.7 mM, pH 7.2) with 250 µl of complete Freund's adjuvant (Statens Seruminstitut; Copenhagen, Denmark). Four months later the mice were immunized regularly (at least five times at 2-week intervals) with IP injections of equal doses of the CD3 complexes, still adsorbed onto the beads, without adding Freund's adjuvant. All mice produced antibodies precipitating CD3{gamma}, CD3{delta}, CD3{varepsilon}, and CD3{omega} proteins as well as molecules with higher (>30,000 Daltons) or lower (<20,000 Daltons) molecular weights (not shown). Five days after the last IP immunization, fusion of the spleen cells with the non-Ig-producing myeloma cell line X63 Ag8 653 was performed using standard techniques (Al Saati et al. 1989 ). When hybridoma growth could be detected, supernatants were tested by cytofluorometry for the presence of MAbs that could recognize permeabilized Jurkat cells (see below). Supernatants from positive hybridomas were tested again in immunoprecipitation experiments with [35S]-methionine/cysteine-labeled Jurkat cell lysates, as described in Geisler et al. 1990 . MAb F7.2.38 (of IgG1 subclass) was selected for further detailed studies because it precipitated proteins with molecular weights similar to those of CD3{gamma}, CD3{delta}, CD3{varepsilon}, and CD3{omega} chains.

Cell lines and MAbs
Human leukemia {alpha}ß (Jurkat subclone E6.1, HBP-ALL, CEM, and MOLT4) and {gamma}{delta} (LYON and PEER) T-cells, human B-lymphoma Raji cells, and murine B-lymphoma FOX cells were grown in RPMI 1640 with L-Glutamate supplemented with 1 mM sodium pyruvate, penicillin/neomycin/streptomycin mixture (Life Technology; Eragny, France), and 8% of fetal calf serum (FCS) (Roche; Meylan, France).

Mouse SP-34, OKT3, and F101.01 MAbs specific for single or CD3-associated CD3{varepsilon} components, respectively, were obtained from Dr. C. Terhorst (Boston, MA), ATCC (Rockville, MD), and Dr. T. Plesner (Copenhagen, Denmark). CD20/L26 anti-B cell MAb and the rabbit polyclonal anti-CD3{varepsilon} (A0452) were purchased from Dako.

Flow Cytometric Analyses
Cells were permeabilized using 0.1% saponin (Sigma; Saint Quentin Fallavier, France). A total of 106 cells were washed in DPBS and labeled for 30 min at 4C with F7.2.38, SP-34, and OKT3 MAbs supplemented with 0.1% saponin. After two washes in DPBS containing 0.1% saponin, cells were incubated for 30 min at 4C with a fluorescein isothiocyanate-conjugated rabbit Fab2' anti-mouse (F0313; Dako) supplemented with 0.1% saponin. Cells were washed in DPBS with 0.1% saponin and analyzed with the Coulter Electronics Cytometer (Coulter EPICS XL; Hialeah, FL).

For surface staining analysis, exactly the same procedure was followed, but without adding saponin, and using a phycoerythrin-conjugated goat anti-mouse (IM0551; Immunotech, Marseille, France) as secondary antibody.

Transfections
Murine B-lymphoma FOX cells were transfected by electroporation. Approximately 5 x 106 cells were washed twice in culture medium without FCS, resuspended in the DNA transfection mixture [5 µg of pSRa-CD3{varepsilon}del12 described by B. Alarcon (Mallabiabarrena et al. 1992 ), linearized by digestion with BamH1, precipitated, and resuspended in 750 µl of the cell culture medium without FCS] and then electroporated in 0.4-cm cuvettes (Ozyme; Montigny, France) at 270 V, 960 µF using a Biorad Gene Pulser apparatus (Bio-Rad; Ivry Sur Seine, France). The cells were carefully resuspended in a 25-cm2 flask containing 10 ml of culture medium. At 48 hr later, 2 mg/ml of G418 (Life Technologies) was added to the medium. When viable cells began to appear (approximately 10 days later), clonings by limiting dilutions were made in the presence of 1 mg/ml of G418. The positive clones were selected by flow cytometry using 0.1% saponin and the anti-CD3{varepsilon} MAb SP-34. In this report, all results shown were obtained with clone T116.4.3.

Western Blotting Experiments
A total of 5 x 106 FOX, T116.4.3, or Jurkat E6.1 cells were washed twice in DPBS and then lysed in 500 µl of Tris 0.5 M, pH 6.8, 2% SDS, 10% glycerol, bromophenol blue, with or without 5% ß-mercaptoethanol. After three 5-sec sonications, lysates were boiled for 10 min at 100C and centrifuged for 10 min at 14000 x g, 4C. Thirty µl of supernatant was separated by SDS-PAGE (12%) according to the Laemmli 1970 . Electrophoresis was followed by transfer of proteins to PVDF membranes (NEN Life Science Products; Paris, France) at 4C, 190 mA, 3 hr. At the end of the electrotransfer, membranes were colored with Ponceau's red to control the quality of the transfer and the loaded samples. Then they were incubated for 1 hr, first with blocking buffer [DPBS; 0.1% Tween-20 (Merck; Fontenay, France), 0.1% gelatin, 5% skimmed milk, and 0.5 g/liter BSA], second with blocking buffer diluted twice and containing SP-34 or F7.2.38 MAb supernatant diluted 10 times. Then membranes were washed three times for 5 min in DPBS with 0.1% Tween-20, and bound antibodies were detected with HRP-conjugated rabbit anti-mouse Ig (P0161; Dako). Peroxidase activity was revealed using an Enhanced Chemiluminescence Detection system (Amersham Pharmacia Biotech).

Immunostaining of Various Human Normal and Neoplastic Tissue Sections
F7.2.38 supernatant diluted 1:10 was used to study its reactivity on a large panel of a variety of normal and pathological human tissue samples from the tissue bank of the department of Pathology at Purpan Hospital in Toulouse, using the multi-tissue block method (Battifora 1986 ). Tissue samples were fixed in 10% neutral buffered formalin or Duboscq-Brasil (ethanol-based Bouin's fluid), and in a few cases in Bouin's fixative, Bouin Holland, and B5, to assess the fixative dependence of the staining intensity.

Different human tumors (n = 179) were investigated. These included: (a) 110 cases of lymphoid neoplasms [including 89 non-Hodgkin's lymphomas classified according to the REAL and the WHO classifications (Harris et al. 1994 , Harris et al. 2000 ) and 21 cases of Hodgkin's disease (Table 1)]; and (b) 69 cases of non-lymphoid tumors of different categories. In addition, 142 cases of normal or non-neoplastic lymphoid (n = 28) and non-lymphoid (n = 114) tissue samples were investigated to evaluate the reactivity of this antibody in normal human organ tissue specimens.


 
View this table:
[in this window]
[in a new window]
 
Table 1. Reactivity of MAb F7.2.38 with malignant cells of 110 cases of malignant lymphomas and Hodgkin's disease on paraffin-embedded tissue sections classified according to the REAL and WHO classifications (Harris et al. 1994 , Harris et al. 2000 )

Paraffin-embedded sections were immunostained by the streptavidin–biotin–peroxidase complex (ABC) method using Dako StrepABComplex/HRP Duet (mouse/rabbit) kit (K0492; Dako). The antigen retrieval method used heat pretreatment of sections in a 750-W microwave oven (10 min of boiling twice in citrate buffer, pH 6) (Shi et al. 1991 ). In some cases, we also evaluated the immunostaining on paraffin-embedded tissue sections using this antibody with two different immunostains: Techmate 500 (Dako) and Ventana 320/ES (Ventana; Strasbourg, France).


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Characterization of the Molecule Targeted by MAb F7.2.38
Similar Patterns of Proteins Precipitated by Known Anti-CD3{varepsilon} and F7.2.38 MAbs. MAb F7.2.38 was selected because it could (a) recognize the human leukemia T-cell line Jurkat by intracellular staining analyzed by flow cytometry and (b) immunoprecipitate proteins with molecular weights similar to those of the CD3{gamma}, CD3{delta}, CD3{varepsilon}, and CD3{omega} chains from 2% NP-40 lysates of Jurkat cells. All TCR/CD3 proteins except CD3{omega} are usually co-precipitated with an anti-CD3{varepsilon} MAb from a 1% digitonin T-cell lysate. However, if 2% NP-40 is used, only CD3{gamma}, {delta}, {varepsilon}, and {omega} chains are co-precipitated. Therefore, comparable immunoprecipitations with MAb F7.2.38 of either digitonin or NP-40 lysates may indicate whether the MAb is specific for CD3{gamma}{delta}{varepsilon} or CD3{omega} molecules. The results in Fig 1 demonstrate that MAb F7.2.38, like MAb OKT3, co-precipitated three bands corresponding to CD3{gamma}{delta}{varepsilon} and CD3{omega} from NP-40 lysates and no CD3{omega} molecules from digitonin lysates. Consequently, MAb F7.2.38 appeared to react against the CD3{gamma}{delta}{varepsilon} chains rather than CD3{omega}. One difference between the immunoprecipitations with MAbs OKT3 and F7.2.38 was the presence of an additional band of 40 kD in the F7.2.38 immunoprecipitates (arrow). This 40,000-Dalton band was also present in immunoprecipitates with the SP-34 MAb specific for single CD3{varepsilon} chains (data not shown). The same results were obtained when we used MAb F7.2.38 with lysates from other human T-cell lines, such as the {alpha}ß HBP-ALL, CEM, and MOLT4 T-cell lines or the {gamma}{delta} LYON and PEER T-cell lines (data not shown). MAb F7.2.38 did not immunoprecipitate any TCR/CD3-like proteins from Raji B-cell lysates (Fig 1). These data indicate that MAb F7.2.38 reacts similarly to some other anti-CD3{varepsilon} MAbs in both detergents used.



View larger version (84K):
[in this window]
[in a new window]
 
Figure 1. 35S-Immunoprecipitates from E6.1 T-cells and Raji B-cells, prepared with MAbs OKT3 and F7.2.38 and separated under non-reducing conditions in a 12% SDS-PAGE. Using 1% digitonin or 2% NP-40 for cell lysis, very similar patterns of immunoprecipitated proteins are observed with the two MAbs, representing the CD3{gamma}, CD3{delta}, and CD3{varepsilon} chains, and indicating that MAb F7.2.38 is directed against the CD3{varepsilon}. As expected, the additional bands observed using 1% digitonin correspond to the {zeta}2 homodimer, TCRß, TCR{alpha} partially (pg) or totally (tg) glycosylated, and the TCR{alpha}ß dimer, which have been immunoprecipated with the CD3{varepsilon} chain. Similarly, the additional band observed using 2% NP-40 corresponds to the CD3{omega} chain, which has been immunoprecipitated with the CD3{varepsilon} chain. Note also that using 2% NP-40, one additional band of 40 kD (probably corresponding to CD3{varepsilon}2 homodimers) is observed using MAb F7.2.38 (arrow) but not with OKT3. Proteins are indicated at right and standard molecular weights are shown at left.

MAb F7.2.38 Specifically Recognizes the Human CD3{varepsilon} Chain. These results led us to postulate that MAb F7.2.38 could be directed against the CD3{varepsilon} chains or against CD3{gamma}{varepsilon} or CD3{delta}{varepsilon} dimers. Therefore, we transfected the murine B-cell lymphoma FOX with a cDNA encoding a truncated CD3{varepsilon} chain (Mallabiabarrena et al. 1992 ). The transfected cells are designated T116.4.3. We observed that MAb F7.2.38, like MAb SP-34, could stain permeabilized transfected, but not permeabilized untransfected, FOX cells (Fig 2A). MAb OKT3 did not recognize the transfectants because this MAb is specific for a "conformational" CD3{varepsilon} epitope (see Introduction). To confirm these results, a Western blotting experiment was carried out using lysates of the CD3{varepsilon}-expressing FOX cells and blotting the membranes with MAb F7.2.38 or SP-34. Fig 3 shows that a ~40-kD band was revealed by MAb F7.2.38 in T116.4.3 cell lysates but not in FOX cell lysates. The proteins in this band were reduced (in the presence of ß-mercaptoethanol) to a ~20-kD band, indicating that the 40-kD band represented a disulfide-linked homodimer of CD3{varepsilon} chains. In E6.1 cell lysates, MAb F7.2.38 revealed a 20-kD band and a 40-kD band. As before, the 40-kD molecules (but not the 20-kD molecules) were reduced to 20 kD. This 40-kD band appears similar to a corresponding molecule in Fig 1 (arrow). The same pattern was observed when the membranes were blotted with MAb SP-34 (data not shown). Similar results were obtained when immunoprecipitation experiments were performed with lysates of [35S]-methionine/cysteine-labeled cells and MAb SP-34 or F7.2.38. However, the results obtained with MAb F7.2.38 proved more constant than those obtained with MAb SP-34 in Western blotting analysis. In contrast, MAbs F7.2.38 and SP-34 demonstrated equivalent activities against CD3{varepsilon} molecules in [35S]-methionine/cysteine-labeled cell lysates (data not shown).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. CD3{varepsilon} chain labeling by MAb F7.2.38 revealed by flow cytometric analyses. FOX cells either expressing CD3{varepsilon} chains after cDNA-transfection (T116.4.3) or negative for CD3{varepsilon} (wild-type FOX), and E6.1 T-cells were stained with SP-34, OKT3 or F7.2.38 supernatants, with (A) or without (B) cell permeabilization. All three MAbs recognize the cytoplasmic CD3{varepsilon} chain of E6.1 T-cells (A). However, in contrast to MAbs SP-34 and OKT3, MAb F7.2.38 does not detect the extracellular portion of the CD3{varepsilon} chain expressed on E6.1 cells (B). Note that MAb OKT3, directed against a CD3{varepsilon} epitope only present in the TCR/CD3 complex, does not recognize CD3{varepsilon} chain in T116.4.3 cells. The results are shown as logarithm of relative fluorescence (FL1/FL2 LOG) vs cell number (Events). Vertical lines define the limit of upper background fluorescence.



View larger version (66K):
[in this window]
[in a new window]
 
Figure 3. CD3{varepsilon} chain recognition by MAb F7.2.38 revealed by Western blotting. FOX cells either expressing CD3{varepsilon} chains after cDNA transfection (T116.4.3) or negative for CD3{varepsilon} (wild-type FOX) and E6.1 T-cells were lysed in non-reducing (NR) or reducing (R) conditions. Western blotting was performed with F7.2.38 or SP-34 as control (not shown) supernatants. MAb F7.2.38 reveals bands at the expected size for CD3{varepsilon} (20 kD) chains and CD3{varepsilon}2 (40 kD) disulfide-linked homodimers in T116.4.3 and E6.1 lysates. The proteins in the 40-kD bands shifted to 20-kD bands under reducing conditions. The same pattern is obtained with MAb SP-34. Standard molecular weights are shown at right.

MAb F7.2.38 Does Not Recognize the CD3{varepsilon} Chain on the Surface of Cells. The cDNA used for FOX cell transfection experiments encodes the CD3{varepsilon} chain with a deleted endoplasmic reticulum retention signal sequence, which in principle should allow the molecule to be expressed at the cell surface (Mallabiabarrena et al. 1992 ). This deletion explains the small molecular weight difference between T116.4.3 CD3{varepsilon} chain and the E6.1 CD3{varepsilon} chain (Fig 3). However, cell surface staining was detected on T116.4.3 and E6.1 cells with MAb SP-34 but not with MAb F7.2.38 (Fig 2B). Therefore, unlike MAb SP-34, this MAb is most likely directed against the cytoplasmic region of the CD3{varepsilon} chain.

Reactivity of MAb F7.2.38 on Paraffin-embedded Tissue Sections
Normal Human Tissues. In normal lymphoid tissue, MAb F7.2.38 showed strong staining of lymphoid cells in the medulla and cortex of normal thymus (Fig 4A). As expected, only scattered B-lymphocytes in the cortex and medulla were labeled with MAb CD20/L26 (Fig 4B). In human lymph node and tonsil, interfollicular areas containing the T-lymphocytes were strongly stained, well delimiting B-cell follicles in which some small reactive T-cells were labeled (Fig 4C). This reactivity was complementary with immunostaining of B-cell zones using MAb CD20/L26 in lymph node tissue (Fig 4D). With the exception of scattered T-cells, MAb F7.2.38 was unreactive with all other normal human tissues studied (data not shown).



View larger version (132K):
[in this window]
[in a new window]
 
Figure 4. Reactivity of anti-CD{varepsilon} MAb F7.2.38 on paraffin tissue sections of normal and neoplastic human lymphoid tissues. (A,B) Thymus: cortical and medullary thymocytes are strongly reactive with MAb F7.2.38 (A). (B) Same area immunostained by anti-CD20/L26 antibody with only scattered positive B-cells, which predominate in the medulla. (C,D) Reactive lymph node: paracortical area containing T-lymphocytes is selectively labeled with F7.2.38 antibody (C). Note that scattered T-cells within B-cell follicles are also labeled. Staining of the same area with anti-B MAb CD20/L26 (D) shows the opposite staining pattern. (E–H) Four different T-cell lymphomas: T-cell lymphoblastic (E), peripheral T-cell (F), mycosis fungoides (G), and anaplastic large cell lymphoma (H). Note the intense positivity of virtually all neoplastic cells of the four T-cell lymphomas (E–H) with MAb F7.2.38. (H) Immunostaining of the malignant cells is restricted to the cytoplasm and is not membrane-associated. Immunoperoxidase technique with nuclear counterstaining. Bars: A,B = 200 µm; C,D = 250 µm; E,F,H = 20 µm; G = 31.25 µm.

Immunostaining on frozen and paraffin-embedded tissue sections was comparable, and therefore only paraffin sections were used in further experiments. Almost all results obtained with MAb F7.2.38 were comparable to the reference antibody, the rabbit polyclonal anti-CD3{varepsilon} antibody.

Neoplastic Human Tissues
Lymphoid Tumors. The reactivity of MAb F7.2.38 with lymphoid tumors is shown in Table 1. All B-cell lymphomas were negative for F7.2.38 (0+/37), and only small reactive T-cells were strongly positive with this antibody. On the contrary, the majority of T-cell lymphomas [41+/52 (79%)] were positive for MAb F7.2.38 (Fig 4E–4H). As expected, anaplastic large-cell lymphomas (ALCLs) showed a lower rate of immunostaining with this antibody [6+/14 (43%)] in comparison with the other types of T-cell lymphomas [35+/38 (92%)] (Table 1) (Fig 4E–4G). In this group of T-cell lymphomas, only 6/14 cases studied showed a positive staining of a variable percentage of neoplastic cells for F7.2.38. The labeling intensity was also variable from case to case and overall was lower than that obtained in the other types of T-cell lymphomas. It is noteworthy that in 2/6 positive ALCLs, only rare neoplastic cells showed weak cytoplasmic staining with MAb F7.2.38. Of note was the reactivity of MAb F7.2.38 with nasal type extranodal NK/T-cell lymphoma. In this last category, 3/5 cases studied were positive for MAb F7.2.38 (Table 1) and virtually all neoplastic cells were labeled (data not shown). Lastly, among the 21 cases of Hodgkin's disease of different categories, only two cases (9.5%) showed focal cytoplasmic staining of a variable number of Hodgkin and Reed–Sternberg cells. In the other cases, neoplastic cells were clearly negative and were often surrounded by strongly labeled small T-lymphocytes.

Non-lymphoid Tumors. The 69 non-lymphoid tumors investigated were always negative for MAb F7.2.38, which stained only small reactive T-cells (data not shown). The same results were obtained with the polyclonal anti-CD3{varepsilon} antibody.

The F7.2.38 antibody worked well on paraffin sections stained either manually, or with either of two automated immunostainers (TechMate 500 and Ventana 320/ES).


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

In this article we have described a novel MAb, F7.2.38, which recognizes the human CD3{varepsilon} chain, associated or not with the TCR/CD3 complex. This MAb can be used for all biochemical and immunohistochemical methods in T-cell receptor research and in routine clinical laboratory tests. Our results show that MAb F7.2.38 recognizes both monomeric and dimeric forms of the CD3{varepsilon} chain (see Fig 3). The latter form is dominant in the CD3{varepsilon} cDNA-transfected non-T-cells compared to normal T-lymphocytes, in which all components of the TCR/CD3 complex are present. These results are in agreement with those described by others (Pessano et al. 1985 ; Alarcon et al. 1991 ; Salmeron et al. 1991 ; Huppa and Ploegh 1997 ).

The main result from this study is that MAb F7.2.38 is directed against a fixative-resistant epitope of the CD3{varepsilon} polypeptide. Therefore, it can be used to identify normal and neoplastic T-cells on paraffin-embedded tissue sections. The reactivity of the polyclonal anti-CD3{varepsilon} antibody on routinely processed biopsy specimen made it a valuable reagent for identification of T-cell lymphoid malignancies. The reactivity of MAb F7.2.38 was very similar to that of the routinely used polyclonal anti-CD3{varepsilon} antiserum. It is of interest that almost all T-cell neoplasms other than anaplastic large-cell lymphoma express CD3 antigen on the surface and/or in the cytoplasm, whereas B-cell lymphomas are invariably negative. As previously reported (Benharroch et al. 1998 ), ALCLs are positive for anti-CD3{varepsilon} antibody in approximately one third of cases. In addition, in this group of T-cell lymphomas the staining intensity and the percentage of positive cells are always lower than those observed in the other T-cell lymphoma subtypes. It is also of interest to note the cytoplasmic staining of three out of the five nasal type extranodal NK/T-cell lymphoma cases. As previously reported (Jaffe et al. 1996 ), in this category of T-cell lymphomas cytoplasmic CD3 is often detected using polyclonal antiserum to CD3{varepsilon} in paraffin sections despite the lack of CD3 detection on the cell membrane. This latter finding is likely consistent with the cytoplasmic expression of CD3{varepsilon} chain by the majority of NK-cells, from which these lymphomas originate (Lanier et al. 1992 ). Finally, in Hodgkin's disease, which is now considered to be a neoplasm of B-cell origin (Kanzler et al. 1996 ), the CD3{varepsilon} reactivity of Reed–Sternberg cells in some cases appears as a globular and not as a diffuse cytoplasmic staining, as previously reported (Cibull et al. 1989 ; Al Saati et al. 1997 ).

Until now, the polyclonal anti-CD3{varepsilon} has been the most commonly used antibody in immunohistochemistry on paraffin sections, giving specific and intense staining of reactive and neoplastic T-cells (Mason et al. 1989 ). It should be noted that, except for MAb F7.2.38, none of the available MAbs directed against the CD3{varepsilon} chain is suitable for use on routinely fixed and paraffin-embedded tissues. This is probably due to the fact that the vast majority of these MAbs (see Salmeron et al. 1991 ) are directed against conformational epitopes, especially in the extracellular domain of the CD3{varepsilon} chain, which could be easily destroyed by fixation of tissues. Interestingly, both the polyclonal anti-CD3{varepsilon} and the F7.2.38 mAb appear to recognize the cytoplasmic region of the CD3{varepsilon}. This unique reactivity provides a valuable tool for functional and immunohistochemical studies. In the present study, we noted that MAb F7.2.38 worked as well as the polyclonal anti-CD3{varepsilon} in immunohistochemical methods, either manually or using automated immunostainers.

In summary, we have produced a novel MAb directed against the human CD3{varepsilon} protein, which would be very useful in studies on TCR/CD3 complex assembly as well as in the immunohistochemical diagnosis of T-cell lymphomas.


  Acknowledgments

Supported by institutional grants from the CNRS, l'Université Paul Sabatier (UPS) Toulouse, and l'Association pour la Recherche contre le Cancer (ARC).

We thank Pr Bill Clark (UCLA) for valuable comments on the manuscript, Dr Balbino Alarcon for the kind gift of the vector pSRa-CD3{epsilon}del12, and Jeanine Boyes, Françoise Dupic, and Dr Andres Alcover for their excellent technical advice. We acknowledge the initial help of Cécile Gouaillard in this project.

Received for publication June 16, 2000; accepted August 10, 2000.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Alarcon B, Ley SC, Sanchez–Madrid F, Blumberg RS, Ju ST, Fresno M, Terhorst C (1991) The CD3{gamma} and CD3{gamma} subunits of the T-cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes. EMBO J 10:903-912[Abstract]

Al Saati T, Caspar S, Brousset P, Chittal S, Caverivière P, Hounieu H, Dastugue N, Idoipe JB, Icart J, Mazerolles C, Delsol G (1989) Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice. Blood 74:2476-2485[Abstract]

Al Saati T, Galoin S, Gravel S, Lamant L, Roda D, Chittal SM, Delsol G (1997) IgH and TcR-{gamma} gene rearrangements identified in Hodgkin's disease by PCR demonstrate lack of correlation between genotype, phenotype and Epstein-Barr virus status. J Pathol 181:387-393[Medline]

Battifora H (1986) Methods in laboratory investigation. The multitumor (sausage) tissue block. Novel method for immunohistochemical testing. Lab Invest 55:244-248[Medline]

Benharroch D, Meguerian–Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier–Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 15:2076-2084

Cibull ML, Stein H, Gatter KC, Mason DY (1989) The expression of the CD3 antigen in Hodgkin's disease. Histopathology 15:599-605[Medline]

Clevers H, Alarcon B, Wileman T, Terhorst C (1988) The T-cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6:629-662[Medline]

Geisler C, Schöller J, Wahi MA, Rubin B, Weiss A (1990) Association of the human CD3-{zeta} chain with the {alpha}ß-T cell receptor/CD3 complex. Clues from a variant with a mutated T cell receptor {alpha} chain. J Immunol 145:1761-1767[Abstract/Free Full Text]

Gold DP, Clevers H, Alarcon B, Dunlaf S, Novotny J, Williams AF, Terhorst C (1987) Evolutionary relationship between the T3 chains of the T-cell receptor complex and the immunoglobulin supergene family. Proc Natl Acad Sci USA 84:7649-7653[Abstract]

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller–Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 36:69-86[Medline]

Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf–Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muuler–Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392[Free Full Text]

Huppa JB, Ploegh HL (1997) In vitro translation and assembly of a complete T cell receptor-CD3 complex. J Exp Med 186:393-403[Abstract/Free Full Text]

Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC (1996) Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103-111[Medline]

Kanzler H, Küppers R, Hansmann ML, Rajewsky K (1996) Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from a (crippled) germinal center cells. J Exp Med 184:1495-1505[Abstract]

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:3405-3407

Lanier LL, Spits H, Phillips JH (1992) The developmental relationship between NK cells and T cells. Immunol Today 13:392-395[Medline]

Mallabiabarrena A, Fresno M, Alarcon B (1992) An endoplasmic reticulum retention signal in the CD3{varepsilon} chain of the T-cell receptor. Nature 357:593-596[Medline]

Manolios N, Letourneur F, Bonifacino JS, Klausner RD (1991) Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. EMBO J 10:1643-1651[Abstract]

Mason DY, Cordell J, Brown M, Pallesen G, Ralfkiaer E, Rothbard J, Crumpton M, Gatter KC (1989) Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol 42:1194-1200[Abstract]

Neisig A, Vangsted A, Zeuthen J, Geisler C (1993) Assembly of the T-cell antigen receptor. Participation of the CD3{omega} chain. J Immunol 151:870-879[Abstract/Free Full Text]

Pessano S, Oettgen H, Bhan AK, Terhorst C (1985) The T3/T cell receptor complex: antigenic distinction between the two 20-kD T3 (T3{delta} and T3{epsilon}) subunits. EMBO J 4:337-344[Abstract]

Pettey CL, Alarcon B, Malin R, Weinberg K, Terhorst C (1987) T3-p28 is a protein associated with the delta and epsilon chains of the T cell receptor-T3 antigen complex during biosynthesis. J Biol Chem 262:4854-4859[Abstract/Free Full Text]

Rubin B, Arnaud J, Caspar–Bauguil S, Conte F, Huchenq A (1994) Biological function of the extracellular domain of the T-cell receptor constant region. Scand J Immunol 39:517-525[Medline]

Salmeron A, Sanchez–Madrid F, Ursa MA, Fresno M, Alarcon B (1991) A conformational epitope expressed upon association of CD3{varepsilon} with either CD3{delta} or CD3{gamma} is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 146:3047-3052

San José E, Sahuquillo AG, Bragado R, Alarcon B (1998) Assembly of the TCR/CD3 complex: CD3{varepsilon}/{delta} and CD3{varepsilon}/{gamma} dimers associate indistinctly with both TCR{alpha} and TCRß chains. Evidence for a double TCR heterodimer model. Eur J Immunol 28:12-21[Medline]

Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748[Abstract]